Tsampasian, Vasiliki, Elghazaly, Hussein, Chattopadhyay, Rahul Kumar, Ali, Omar, Corballis, Natasha, Chousou, Panagiota Anna, Clark, Allan ORCID: https://orcid.org/0000-0003-2965-8941, Garg, Pankaj ORCID: https://orcid.org/0000-0002-5483-169X and Vassiliou, Vassilios ORCID: https://orcid.org/0000-0002-4005-7752 (2022) Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 29 (6). e227–e229. ISSN 2047-4873
Preview |
PDF (F1. CV death or HHF)
- Accepted Version
Download (291kB) | Preview |
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Download (172kB) | Preview |
Preview |
PDF (SupplMaterial_Updated)
- Accepted Version
Download (513kB) | Preview |
Microsoft Word (OpenXML) (Table_updated)
- Accepted Version
Download (15kB) |
Abstract
Whilst heart failure with preserved ejection fraction (HFpEF) is increasingly studied, the search for a single pharmacotherapeutic agent that will improve hard endpoints like hospitalization and mortality still continues.1 Given the various subphenotypes of HFpEF,2 this makes it difficult for a single agent to be universally beneficial. The recent publication of EMPEROR-PRESEVED3 was an instrumental time for an updated meta-analysis focused on sodium glucose co-transporter 2 inhibitors (SGLT2i) use in HFpEF.
Downloads
Downloads per month over past year
Actions (login required)
View Item |